Royal Bank Of Canada Reiterates “Outperform” Rating for Abbott Laboratories (NYSE:ABT)

Abbott Laboratories (NYSE:ABT)‘s stock had its “outperform” rating restated by Royal Bank Of Canada in a report issued on Friday,Benzinga reports. They presently have a $130.00 target price on the healthcare product maker’s stock. Royal Bank Of Canada’s price objective points to a potential upside of 29.09% from the company’s current price.

Several other research analysts have also issued reports on ABT. Mizuho dropped their price objective on Abbott Laboratories from $125.00 to $115.00 and set a “neutral” rating for the company in a research note on Friday, April 17th. The Goldman Sachs Group dropped their target price on shares of Abbott Laboratories from $121.00 to $113.00 and set a “buy” rating for the company in a research report on Wednesday, May 27th. Evercore reduced their price target on shares of Abbott Laboratories from $134.00 to $120.00 and set an “outperform” rating on the stock in a research report on Friday, April 17th. Robert W. Baird began coverage on shares of Abbott Laboratories in a report on Wednesday, July 1st. They set an “outperform” rating and a $121.00 price objective for the company. Finally, TD Cowen cut their target price on shares of Abbott Laboratories from $137.00 to $115.00 and set a “buy” rating for the company in a research note on Friday, April 17th. Three research analysts have rated the stock with a Strong Buy rating, nineteen have issued a Buy rating and four have given a Hold rating to the stock. According to MarketBeat.com, Abbott Laboratories presently has an average rating of “Moderate Buy” and a consensus price target of $118.61.

Abbott Laboratories Stock Performance

NYSE:ABT opened at $100.71 on Friday. The firm has a market capitalization of $175.41 billion, a PE ratio of 32.59, a price-to-earnings-growth ratio of 1.73 and a beta of 0.61. The company has a quick ratio of 1.01, a current ratio of 1.39 and a debt-to-equity ratio of 0.56. Abbott Laboratories has a 12-month low of $81.97 and a 12-month high of $137.49. The firm has a 50-day moving average price of $89.89 and a 200 day moving average price of $102.17.

Abbott Laboratories (NYSE:ABT) last released its quarterly earnings data on Thursday, July 16th. The healthcare product maker reported $1.31 earnings per share for the quarter, beating the consensus estimate of $1.28 by $0.03. Abbott Laboratories had a return on equity of 17.65% and a net margin of 11.65%.The company had revenue of $12.51 billion for the quarter, compared to analyst estimates of $12.52 billion. During the same period in the prior year, the company posted $1.26 EPS. The company’s revenue was up 13.0% compared to the same quarter last year. Abbott Laboratories has set its Q3 2026 guidance at 1.380-1.46 EPS and its FY 2026 guidance at 5.450-5.60 EPS. Research analysts anticipate that Abbott Laboratories will post 5.48 earnings per share for the current fiscal year.

Insider Buying and Selling

In other news, CFO Philip P. Boudreau acquired 2,200 shares of Abbott Laboratories stock in a transaction on Thursday, April 23rd. The shares were purchased at an average price of $91.50 per share, with a total value of $201,300.00. Following the acquisition, the chief financial officer owned 2,200 shares in the company, valued at $201,300. This represents a ∞ increase in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, Director Daniel J. Starks acquired 10,000 shares of the firm’s stock in a transaction on Monday, April 27th. The stock was purchased at an average price of $92.65 per share, for a total transaction of $926,500.00. Following the completion of the transaction, the director directly owned 6,751,103 shares in the company, valued at approximately $625,489,692.95. The trade was a 0.15% increase in their position. The disclosure for this purchase is available in the SEC filing. 0.46% of the stock is currently owned by corporate insiders.

Institutional Trading of Abbott Laboratories

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the company. 4WEALTH Advisors Inc. raised its holdings in Abbott Laboratories by 25.3% during the 2nd quarter. 4WEALTH Advisors Inc. now owns 9,520 shares of the healthcare product maker’s stock worth $883,000 after purchasing an additional 1,923 shares during the last quarter. Liberty Capital Management Inc. bought a new position in shares of Abbott Laboratories in the 2nd quarter valued at about $3,140,000. Merit Financial Group LLC grew its position in shares of Abbott Laboratories by 22.0% during the 2nd quarter. Merit Financial Group LLC now owns 77,835 shares of the healthcare product maker’s stock worth $7,063,000 after buying an additional 14,030 shares during the period. Vaquero Private Wealth Ltd. bought a new stake in shares of Abbott Laboratories during the second quarter worth approximately $180,000. Finally, Farther Finance Advisors LLC lifted its holdings in Abbott Laboratories by 1.5% in the second quarter. Farther Finance Advisors LLC now owns 73,946 shares of the healthcare product maker’s stock valued at $6,714,000 after buying an additional 1,128 shares during the period. 75.18% of the stock is currently owned by institutional investors and hedge funds.

More Abbott Laboratories News

Here are the key news stories impacting Abbott Laboratories this week:

• Positive Sentiment: Abbott beat Q2 earnings expectations and raised 2026 adjusted EPS guidance to $5.45-$5.60, signaling better profit momentum for the rest of the year. Abbott Reports Second-Quarter 2026 Results and Raises Full-Year EPS Guidance
• Positive Sentiment: Management pointed to stronger second-half demand across multiple businesses, including nutrition, medical devices, diagnostics, and diabetes care, which supports a faster growth profile. ABT Q2 Earnings Call Flags Stronger Second-Half Setup
• Positive Sentiment: Analysts turned more constructive after the results, with JPMorgan, Citi, Piper Sandler, Wells Fargo, TD Cowen, BTIG, and RBC all lifting targets or reaffirming bullish views. These Analysts Increase Their Forecasts On Abbott Following Better-Than-Expected Q2 Results

Abbott Laboratories Company Profile

Abbott Laboratories is a global healthcare company headquartered in Abbott Park, Illinois, that develops, manufactures and markets a broad portfolio of medical products and services. Founded in 1888, Abbott operates through multiple business areas that focus on diagnostics, medical devices, nutritionals and established pharmaceuticals. The company supplies hospitals, clinics, laboratories, retailers and direct-to-consumer channels with products intended to diagnose, treat and manage a wide range of health conditions.

In diagnostics, Abbott provides laboratory and point-of-care testing platforms and assays used to detect infectious diseases, chronic conditions and biomarkers; its Alinity family of instruments and rapid-test solutions are examples of this capability.